569 results about "ELISA unit" patented technology

The present invention provides prognostic and diagnostic methods for cancer, as well as methods for monitoring or staging cancer. Methods involve assaying for tumor-derived soluble MIC polypeptide—either MICA or MICB or both—in a sample from a subject. Assays can be implemented with a MIC polypeptide binding agent such as a MIC polypeptide antibody or recombinant NKG2D. An ELISA sandwich assay is employed in some embodiments of the invention to identify a soluble MIC polypeptide. In additional embodiments, a sample is assayed for tumor cell-surface bound MIC in addition to assaying for soluble MIC. The invention also provides methods of cancer therapy involving detecting cancer in the subject by assaying for soluble MIC polypeptide and then administering a cancer therapy.

This invention provides a method of detecting pathogens comprising the steps of: (a) contacting a sufficient amount of biofunctional magnetic nanoparticles with an appropriate sample for an appropriate period of time to permit the formation of complexes between the pathogens in the sample and the nanoparticles; (b) using a magnetic field to aggregate said complexes; and (c) detecting said complexes. The method may further comprise the additional step of removing said complexes. The biofunctional magnetic nanoparticles are preferably a conjugate of vancomycin and FePt. The pathogens may be bacteria or viruses, and the sample may be a solid, liquid, or gas. Detection may involve conventional fluorescence assay, enzyme-linked immunosorbent assay (ELISA), optical microscope, electron microscope, or a combination thereof. The sensitivity of detection for the method is at least as low as 10 colony forming units (cfu) of the pathogens in one milliliter of solution within one hour.

Monoclonal antibody reagents that recognize the SARS-coronavirus (SARS-HCoV) are needed urgently. In this report we describe the development and immunochemical characterisation of mAbs against the SARS-HCoV based upon their specificity, binding requirements, and biological activity. Initial screening by ELISA, using highly purified virus as the coating antigen, resulted in the selection of seventeen mAbs. Five mAbs exhibited Western immunoblot reactivity with the denatured spike protein, of which two demonstrated the ability to neutralize SARS-HCoV in vitro. Another four Western immunoblot-negative mAbs also neutralize the virus. These antibodies will be useful for the development of diagnostic tests, pathogenicity and vaccine studies.

A monoclonal or polyclonal antibody directed against urokinase plasminogen activator receptor (u-PAR), or a subsequence, analogue or glycosylation variant thereof. Antibodies are disclosed which react with free u-PAR or with complexes between u-PA and u-PAR and which are capable of 1) catching u-PAR in ELISA, or 2) detecting u-PAR, e.g. in blotting, or 3) in radioimmunoprecipitation assay precipitate purified u-PAR in intact or fragment form, or 4) is useful for immunohistochemical detection of u-PAR, e.g. in immunostaining of cancer cells, such as in tissue sections at the invasive front, or 5) inhibits the binding of pro-u-PA and active u-PA and thereby inhibits cell surface plasminogen activation. Methods are disclosed 1) for detecting or quantifying u-PAR, 2) for targeting a diagnostic to a cell containing a u-PAR on the surface, 3) for preventing or counteracting proteolytic activity in a mammal. Methods for for selecting a substance suitable for inhibiting u-PA/u-PAR interaction, for preventing or counteracting localized proteolytical activity in a mammal, for inhibiting the invasion and/or metastasis comprise the use of the antibodies and of nude mice inoculated with human cancer cells which are known to invade and/or metastasize in mice and having a distinct color, f.x. obtained by means of an enzyme and a chromogenic substrate for the enzyme, the color being different from the cells of the mouse.

A group of compounds that inhibit HIV replication by blocking HIV entry was identified. One representative compound, designated NB-206, and its analogs inhibited HIV replication (p24 production) with IC₅₀ values at nanomolar levels. It was proved that NB-206 and its analogs are HIV entry inhibitors by targeting the HIV gp41 since: 1) they inhibited HIV-mediated cell fusion; 2) they inhibited HIV replication only when they were added to the cells less than one hour after virus addition; 3) they blocked the formation of the gp41 core that is detected by sandwich enzyme linked immunosorbent assay (ELISA) using a conformation-specific MAb NC-1; and 4) they inhibited the formation of the gp41 six-helix bundle revealed by fluorescence native-polyacrylamide gel electrophoresis (FN-PAGE). These results suggested that NB-206 and its analogs may interact with the hydrophobic cavity and block the formation of the fusion-active gp41 coiled coil domain, resulting in inhibition of HIV-1 mediated membrane fusion and virus entry.

The present invention relates to assay methods used for detecting the presence of PIF, and to PIF peptides identified using this assay. In particular, the present invention relates to flow cytomery assays for detecting PIF. It is based, at least in part, on the observation that flow cytometry using fluorescently labeled antilymphocyte and anti-platelet antibodies demonstrated an increase in rosette formation in the presence of PIF. It is further based on the observation that flow cytometry demonstrated that monoclonal antibody binding to CD2 decreased in the presence of PIF. The present invention further relates to PIF peptides which, when added to Jurkat cell cultures, have been observed to either (I) decrease binding of anti-CD2 antibody to Jurkat cells; (ii) increase expression of CD2 in Jurkat cells; or (iii) decrease Jurkat cell viability. In additional embodiments, the present invention provides for ELISA assays which detect PIF by determining the effect of a test sample on the binding of anti-CD2 antibody to a CD2 substrate.

The invention provides an aflatoxin B1 (AFB1) magnetic separation enzyme-linked immunity quantitative detection method, belonging to the field of food safety immunoassay technique. The method adopts the immuno-detection principle of competition law; and AFB1 is connected with biological enzyme to prepare enzyme-labeled antigen reagent, anti-fluorescein isothiocyanate (FITC) antibody is absorbed onthe surfaces of magnetic particles to prepare magnetic separation reagent, and the FITC is connected with the AFB1 antibody to prepare anti-reagent. In a sample, the AFB1 competes with the enzyme-labeled AFB1 and is combined with a small amount of FITC-labeled anti-AFB1 antibody, so that antigen-antibody complex can be formed. After the magnetic separation reagent is added, the complex is caughtonto the surfaces of the magnetic particles by the anti-FITC antibody connected on the surfaces of the magnetic particles. After being washed, the product is finally added with substrate and detected.The method has the advantages that (1) the magnetic particles are used for replacing the traditional enzyme-labeled plate to be taken as a solid-phase carrier, so that immunoreaction is carried out under the approximate liquid phase condition; and the reaction is more complete and rapid, and has the characteristics of high specificity and good repeatability compared with the traditional enzyme-linked immuno sorbent assay (ELISA); furthermore, (2) by adopting one-step competition law principle, the time used for detection is short.

The present invention is directed to antigenic peptides and peptide compositions selected from the Membrane glycoprotein (M), the Spike glycoprotein (S), and the Nucleocapsid (N) protein antigens of the SARS coronavirus (SCoV). The present invention is also directed to methods of use of the peptides of the invention, e.g., for the detection of SARS-associated antibodies. Detection methods include enzyme-linked immunosorbent assay (ELISA) or other immunoassay procedures.

The present invention relates to a hybridoma cell line 3G1 and an anti-alfatoxin B1 monoclonal antibody produced by the hybridoma cell line 3G1. The hybridoma cell line 3G1 (CCTCCNO.C201014) can be used for preparation of a high titer anti-aflatoxin B1 monoclonal antibody, wherein an enzyme-linked immunosorbent assay (ELISA) method is adopted to determine a titer, and the titer is 6.40*10<6>. The anti-aflatoxin B1 monoclonal antibody of the present invention has characteristics of high sensitivity and good specificity, wherein 50% inhibiting concentration on aflatoxin B1 by the monoclonal antibody is 1.6 ng/mL, cross reaction rate with aflatoxin B2 is 6.4%, and cross reaction rates with aflatoxin G1 and G2 are less than 1%. In addition, the anti-aflatoxin B1 monoclonal antibody of the present invention can be used for determination of aflatoxin B1.

This invention relates to a rapid and efficient method for carrying out enzyme-linked immunosorbent assay for detection of minute quantities of biomolecules such as antigen, antibody etc. This invention particularly relates to microwave mediated immobilization of antigen or antibody on to the activated surface followed by performing subsequent steps of ELISA by controlled microwave irradiation. The invented procedure has dramatically reduced the total time required for ELISA to less than 10 minutes from hours to days. The invented ELISA procedure is rapid, economical, reproducible and simple and can be automated. The invented procedure is useful for carrying out ELISA in clinical diagnostics, molecular biology, agriculture, sericulture, food technology, environmental science, biomedical research and other related fields.

The invention discloses an enzyme immunoassay of testing the bice green residues in animal derived food, which comprises an enzyme label plate covering bice green antigen, enzyme label bice green antibody working solution, bice green standard solution, substrate solution, substrate buffer solution, reaction termination solution, concentration washing liquid and sample dilute solution. The invention further discloses a method for using the immunoassay to test bice green residues, which comprises sample pretreatment, testing via the immunoassay, processing and analyzing result. The inventive immunoassay of bice green test uses direct competition enzyme-linked immunoassay adsorption analysis technique, with high sensitivity, high stability, simplified operation, reduced reaction time, reduced error caused by complex operation, reduced cost, wide application for testing samples and high practicality.

The invention relates to a nano probe based method for detecting trace proteins by using a microfluidic chip, which is characterized by comprising the steps: manufacturing a microstructure by using a standard photoetching process, and sealing a glass sheet (spotted with a DNA (deoxyribonucleic acid) probe) and the microstructure to prepare a required microfluidic chip; simultaneously labeling a monoclonal secondary antibody and a Barcode DNA with a signal amplification function on a nano gold particle, and labeling a monoclonal primary antibody on a magnetic bead; and detecting the trace target proteins in a microfluidic chip channel by means of immunoreaction of antigens and antibodies as well as gradual amplification and silver staining development of signals. The nano probe based method provided by the invention integrates the procedures of enrichment, separation and detection of biological samples, has the characteristics of specificity, rapidness and high sensitivity, and is expected to be applied to the diagnosis and detection of trace proteins (the antigens or antibodies) in clinical laboratory medicine. The sensitivity can reach a pg/ml level and is improved by 1000 times compared with the common ELISA (enzyme-linked immunosorbent assay) method in clinical application.

A PCV2 antigen or antibody kit for detecting ELISA is composed of antigen detection plate, enzyme conjunctive matter working solution, positive control, negative control, sample diluent, 10 x concentrated cleaning solution, colour development solution A and B as well as stop buffer.

An assay exhibiting improved sensitivity for achieving a factor of ten times (10×) better sensitivity than current sensitivity levels achieved by prior-art immunoassays, as exemplified by ELISA. Three main implementations are described: IA/MPD, Super-ELISA and Reverse Geometry Immunoassay, including specific panel biomarker relationships for the early detection and recognition patterns of breast and prostate cancers. More sensitive immunoassays are achieved through a better understanding of sources of biological background, and by the rejection of particular sources thereof. Super-sensitive immunoassays permit measurement of blood sample biomarkers, and show distribution of low abundance proteins included relationships between cytokine non-Gaussian distributions, very large dynamic ranges and strong age dependence, and including new algorithms based on 2D correlations of studied biomarkers.

The invention relates to a PCV2 (porcine circovirus 2) ELISA (enzyme-linked immuno sorbent assay) antigen detection kit as well as a preparation method and applications thereof, wherein the detection kit comprises an elisa plate of a polyclonal antibody of peridium anti-PCV2-Cap (nucleocapsid) protein, seal liquids, sample diluent, an antigen standard product, a second antibody of a monoclonal antibody of HRP marked anti-PCV2-Cap protein, a concentrated washing liquid, an enzyme substrate solution A, an enzyme substrate solution B and a stop solution, wherein the antigen standard product is purified reconstructed PCV2-Cap protein. The specificity of the kit provided by the invention achieves 100%, and the sensitivity is as high as 4ng/ml, and the kit can be used for swinery PCV2 antigen detection and PCV2 vaccine product quantitative detection.

The invention discloses a method for detecting the specific antibody of classical swine fever virus and a special ELISA kit thereof. The kit includes a classical swine fever virus antigen and an enzyme-labeled classical swine fever virus single-epitope specific antibody; the said swine fever virus antigen is a polypeptide containing one or more than one amino acid residue sequence described in sequence 1. The detection reagent of the classical swine fever virus specific antibody of the present invention can carry out effective detection to the classical swine fever virus specific antibody by solid-phase antigen competition ELISA (blocking method); The B cell epitope ensures the differential diagnosis, and the high degree of conservation of the epitope among various strains ensures the specificity of detection.

The invention discloses a method and a device for detecting and separating HP ELISA. According to the method, a prepared magnetic bead provided with HP, an enzyme-labeled antibody, an enzyme reaction substrate, a gastric juice sample and a cleaning fluid are placed in different liquid storage tanks on a micro-fluidic chip by the aid of an electric fluid force, and flow of liquids in the different liquid storage tanks is electrically controlled , so that ELISA is fully and automatically detected; and a detected fluorescence signal is taken as a trigger signal, so that an HP sample is fully and automatically separated. The device comprises a platform structure, the micro-fluidic chip and an electric cabinet, wherein the micro-fluidic chip comprises a glass sheet, a PDMS (polydimethylsiloxane) square plate and a driving electrode, a micro channel, a mixed channel and a detection area are formed in the surface of the PDMS square plate in a photoetching manner by the aid of a soft lithography technology, and the liquid storage tanks are arranged on the PDMS square plate. The device for detecting and separating the HP ELISA has the advantages as follows: the device is small in size, light in weight, convenient to carry and operate and low in construction cost and can be handheld for field detection, thereby facilitating popularization and application.

The invention discloses an indirect competitive enzyme-linked immunosorbent assay (ELISA) for measuring heavy metal mercury, belonging to a method for measuring heavy metal mercury in an environment water sample. The method comprises the following steps: taking a monoclonal antibody for specially identifying mercury-chelating agent EDTA compound Hg-EDTA as the base, coating the coated antigen mercury-chelating agent-albumen on a 96-hole ELISA plate; incubating at 4 DEG C over night and then sealing by phosphate buffer solution PBS including 1% of gelatin, after washing the ELISA plate, addinga mixing solution of the specificity mercury monoclonal antibody and samples to be measured, incubating at 37 DEG C and then washing the plate, adding an ELISA secondary antibody, incubating at 37 DEGC, adding an enzyme reaction substrate after washing the plate, and adding a reaction stop solution for stopping the reaction after the incubation, and then measuring the absorbance value of each hole by an ELISA reader; obtaining a standard competitive inhibit curve, then executing Logit transition on the curve, and drawing the standard curve of the mercury in the sample to carry out the quantitative analysis. The method is suitable for the measurement of trace mercury in an environment water sample, simultaneously provides the technical support for the fast scene measurement of heavy metalpollution emergency in order to remedy the pollution accident and go back to work in time.

The invention relates to a biologically safe Africa swine fever antigen multifactorial serum for ELISA (enzyme-linked immuno sorbent assay) diagnosis. A technical scheme adopted in the invention includes: adopting gene-expressed structural protein P72, K205R, P54, and A104R, conducting chemical purification, carrying out coating with a Freund's incomplete adjuvant, performing intramuscular immunization on laboratory swine in three batches, collecting swine blood after one month, separating serum, implementing serological testing, and conducting subpackaging and preservation. The serum is subpackaged into ELISA kits to undergo test according to conventional ELISA test methods.

The vascular endothelial growth factor (VEGF) activity in a patient's bloodstream or other biological sample can serve as a diagnostic and prognostic index for cancer, diabetes, heart conditions, and other pathologies. Antibody-sandwich ELISA methods and kits for VEGF as an antigen are provided to detect types of VEGF levels in biological samples from animal models and human patients and can be used as a diagnostic/prognostic index.

The invention discloses a Korean novel duck hepatitis viral antibody ELISA (Enzyme-Linked Immunosorbent Assay) detection kit. The detection kit contains an ELISA board coated by Korean novel duck hepatitis VP1 (Phenotypic Variance1) recombination protein, a sample diluent, concentrated washing liquid, an enzyme conjugate working solution, a chromogenic reagent (A), a chromogenic reagent (B), a stopping solution, a positive contrast solution and a negative contrast solution. The VP1 recombination protein is obtained by using the following method: using Korean novel duck hepatitis viruses as a material, augmenting and cloning the VP1 gene through an RT-PCR (Reverse Transcriptase-Polymerase Chain Reaction) method to obtain recombinant expression plasmid pMD (physical medium dependent)-VP1; then, directionally inserting to an expression vector pET-32a (+) and screening to obtain recombinant expression plasmid pET-32a(+)-VP1; and inducing, expressing and purifying by ITPG (Isopropyl beta-D-Thiogalactopyranoside) to obtain VP1 recombination protein. The detection kit is used for detecting the Korean novel duck hepatitis and has strong specificity, high sensitivity, simplicity of operation, easiness of popularization and application in a large-area range and wide market prospects.